SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. Collectively, these studies expand the evidence supporting MMAI’s potential to deliver consistent, biologically meaningful insights across diverse patient populations and clinical settings. The findings carry implications for more personal